FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335183960> ?p ?o ?g. }

• W2335183960 endingPage "658" @default.
• W2335183960 startingPage "658" @default.
• W2335183960 abstract "Introduction: There were conflicting results regarding the nondepolarizing neuromuscular blocking agent requirements during liver transplantation. We tried to evaluate the requirement according to the operation phase and find the extrahepatic factors which influence the neuromuscular blocking agent requirements. Methods: Thirty-five patients undergoing living donor liver transplantation were enrolled. Continuous infusion of vecuronium was used, which was adjusted every 15 min for consistent neuromuscular blockade aimed at T1/Tc of 0.10 monitored with neuromuscular transmission module (M-NMT Module®, Datex-Ohmeda Inc, Helsinki, Finland). The mean infusion dose of each phase was calculated and compared. The vecuronium infusion dose was investigated whether it is correlated with preoperative MELD score, CTP score, graft-recipient weight ratio or time to recovery of first twitch response of TOF stimulation. Results: There was a statistically significant difference between vecuronium infusion dose at each phase (p < 0.001): 0.48 ± 0.16 μg/kg/min during preanhepatic phase, 0.38 ± 0.14 μg/kg/min during anhepatic phase, and 0.26 ± 0.07 μg/kg/min during neohepatic phase. There was a significant positive correlation between vecuronium infusion dose of preanhepatic phase and CTP scores (p = 0.006, correlation coefficient = 0.465). There was also significant negative correlation between the time to recovery of first twitch response of TOF stimulation and vecuronium infusion dose of preanhepatic phase (p = 0.001, correlation coefficient = -0.546). The infusion dose of preanhepatic phase was not associated with MELD score, and that of neohapatic phase was not associated with GRWR. Conclusions: The vecuronium infusion dose during preanhepatic phase was reduced during the anhepatic phase. Notably, it further decreased during the neohepatic phase compared with the previous phases. Vecuronium infusion dose reduction is suggested especially during neohepatic phase for early extubation. The dose during preanhepatic phase is suggested to be determined considering CTP score and time to recovery of TOF response.Figure: [Vcuronium infusion dose at each operation phase]" @default.
• W2335183960 created "2016-06-24" @default.
• W2335183960 creator A5006055991 @default.
• W2335183960 creator A5025164807 @default.
• W2335183960 creator A5033142661 @default.
• W2335183960 creator A5050471798 @default.
• W2335183960 creator A5050483439 @default.
• W2335183960 creator A5089313716 @default.
• W2335183960 date "2012-11-01" @default.
• W2335183960 modified "2023-10-17" @default.
• W2335183960 title "Vecuronium Requirements According to the Operation Phase During Living Donor Liver Transplantation Under Desflurane Anaesthesia" @default.
• W2335183960 doi "https://doi.org/10.1097/00007890-201211271-01285" @default.
• W2335183960 hasPublicationYear "2012" @default.
• W2335183960 type Work @default.
• W2335183960 sameAs 2335183960 @default.
• W2335183960 citedByCount "0" @default.
• W2335183960 crossrefType "journal-article" @default.
• W2335183960 hasAuthorship W2335183960A5006055991 @default.
• W2335183960 hasAuthorship W2335183960A5025164807 @default.
• W2335183960 hasAuthorship W2335183960A5033142661 @default.
• W2335183960 hasAuthorship W2335183960A5050471798 @default.
• W2335183960 hasAuthorship W2335183960A5050483439 @default.
• W2335183960 hasAuthorship W2335183960A5089313716 @default.
• W2335183960 hasBestOaLocation W23351839601 @default.
• W2335183960 hasConcept C141071460 @default.
• W2335183960 hasConcept C206044474 @default.
• W2335183960 hasConcept C2779609443 @default.
• W2335183960 hasConcept C2909465803 @default.
• W2335183960 hasConcept C2911091166 @default.
• W2335183960 hasConcept C3018112808 @default.
• W2335183960 hasConcept C3020341438 @default.
• W2335183960 hasConcept C42219234 @default.
• W2335183960 hasConcept C71924100 @default.
• W2335183960 hasConceptScore W2335183960C141071460 @default.
• W2335183960 hasConceptScore W2335183960C206044474 @default.
• W2335183960 hasConceptScore W2335183960C2779609443 @default.
• W2335183960 hasConceptScore W2335183960C2909465803 @default.
• W2335183960 hasConceptScore W2335183960C2911091166 @default.
• W2335183960 hasConceptScore W2335183960C3018112808 @default.
• W2335183960 hasConceptScore W2335183960C3020341438 @default.
• W2335183960 hasConceptScore W2335183960C42219234 @default.
• W2335183960 hasConceptScore W2335183960C71924100 @default.
• W2335183960 hasIssue "10S" @default.
• W2335183960 hasLocation W23351839601 @default.
• W2335183960 hasOpenAccess W2335183960 @default.
• W2335183960 hasPrimaryLocation W23351839601 @default.
• W2335183960 hasRelatedWork W1965468760 @default.
• W2335183960 hasRelatedWork W1988110933 @default.
• W2335183960 hasRelatedWork W1996626710 @default.
• W2335183960 hasRelatedWork W2002865831 @default.
• W2335183960 hasRelatedWork W2063306954 @default.
• W2335183960 hasRelatedWork W2349531292 @default.
• W2335183960 hasRelatedWork W2353864966 @default.
• W2335183960 hasRelatedWork W2385550039 @default.
• W2335183960 hasRelatedWork W4328017398 @default.
• W2335183960 hasRelatedWork W62785964 @default.
• W2335183960 hasVolume "94" @default.
• W2335183960 isParatext "false" @default.
• W2335183960 isRetracted "false" @default.
• W2335183960 magId "2335183960" @default.
• W2335183960 workType "article" @default.